

Benjamin Mordmüller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1964903/publications.pdf>

Version: 2024-02-01

191
papers

10,546
citations

41344

49
h-index

40979

93
g-index

201
all docs

201
docs citations

201
times ranked

10746
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. <i>Lancet</i> , The, 2015, 386, 31-45.	13.7	1,127
2	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. <i>New England Journal of Medicine</i> , 2011, 365, 1863-1875.	27.0	773
3	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. <i>New England Journal of Medicine</i> , 2012, 367, 2284-2295.	27.0	653
4	Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. <i>PLoS Medicine</i> , 2014, 11, e1001685.	8.4	367
5	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	27.0	355
6	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. <i>Nature</i> , 2017, 542, 445-449.	27.8	332
7	Atypical and classical memory B cells produce <i>Plasmodium falciparum</i> neutralizing antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 389-399.	8.5	200
8	Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. <i>Lancet</i> , The, 1998, 351, 265-266.	13.7	165
9	Hemozoin (Malarial Pigment) Inhibits Differentiation and Maturation of Human Monocyte-Derived Dendritic Cells: A Peroxisome Proliferator-Activated Receptor- β -Mediated Effect. <i>Journal of Immunology</i> , 2004, 173, 4066-4074.	0.8	156
10	Nitric Oxide Synthase 2 (Lambar α (G α 954C), Increased Nitric Oxide Production, and Protection against Malaria. <i>Journal of Infectious Diseases</i> , 2001, 184, 330-336.	4.0	152
11	The I κ B Kinase Complex and NF- κ B Act as Master Regulators of Lipopolysaccharide-Induced Gene Expression and Control Subordinate Activation of AP-1. <i>Molecular and Cellular Biology</i> , 2004, 24, 6488-6500.	2.3	152
12	Progress with <i>Plasmodium falciparum</i> sporozoite (PfSPZ)-based malaria vaccines. <i>Vaccine</i> , 2015, 33, 7452-7461.	3.8	152
13	Selection of a trioxaquine as an antimalarial drug candidate. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17579-17584.	7.1	135
14	Clonal selection drives protective memory B cell responses in controlled human malaria infection. <i>Science Immunology</i> , 2018, 3, .	11.9	132
15	Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies. <i>Immunity</i> , 2017, 47, 1197-1209.e10.	14.3	129
16	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. <i>Nature Communications</i> , 2019, 10, 2174.	12.8	123
17	Experimental infection of human volunteers. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e312-e322.	9.1	120
18	Lymphotoxin and lipopolysaccharide induce NF- κ B p52 generation by a co-translational mechanism. <i>EMBO Reports</i> , 2003, 4, 82-87.	4.5	118

#	ARTICLE	IF	CITATIONS
19	Natural infection of <i>Plasmodium brasilianum</i> in humans: Man and monkey share quartan malaria parasites in the Venezuelan Amazon. <i>EBioMedicine</i> , 2015, 2, 1186-1192.	6.1	115
20	Direct venous inoculation of <i>Plasmodium falciparum</i> sporozoites for controlled human malaria infection: a dose-finding trial in two centres. <i>Malaria Journal</i> , 2015, 14, 117.	2.3	114
21	First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria. <i>Clinical Infectious Diseases</i> , 2019, 69, 1509-1516.	5.8	111
22	Neutrophil extracellular traps drive inflammatory pathogenesis in malaria. <i>Science Immunology</i> , 2019, 4, .	11.9	108
23	Safety and immunogenicity of GMZ2 – a MSP3–GLURP fusion protein malaria vaccine candidate. <i>Vaccine</i> , 2009, 27, 6862-6868.	3.8	98
24	Notch ligands Delta-like1, Delta-like4 and Jagged1 differentially regulate activation of peripheral T helper cells. <i>European Journal of Immunology</i> , 2005, 35, 2443-2451.	2.9	97
25	Comprehensive study of proteasome inhibitors against <i>Plasmodium falciparum</i> laboratory strains and field isolates from Gabon. <i>Malaria Journal</i> , 2008, 7, 187.	2.3	94
26	Fixed-Dose Pyronaridine–Artesunate Combination for Treatment of Uncomplicated <i>Falciparum</i> Malaria in Pediatric Patients in Gabon. <i>Journal of Infectious Diseases</i> , 2008, 198, 911-919.	4.0	91
27	Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. <i>Science</i> , 2018, 360, 1358-1362.	12.6	89
28	A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children. <i>Vaccine</i> , 2016, 34, 4536-4542.	3.8	86
29	Antischistosome IgG4 and IgE Responses Are Affected Differentially by Chemotherapy in Children versus Adults. <i>Journal of Infectious Diseases</i> , 1996, 173, 1242-1247.	4.0	84
30	DSM265 for <i>Plasmodium falciparum</i> chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 636-644.	9.1	83
31	Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. <i>Journal of Experimental Medicine</i> , 2018, 215, 63-75.	8.5	79
32	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. <i>Nature Communications</i> , 2021, 12, 324.	12.8	79
33	Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved <i>Plasmodium falciparum</i> sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates. <i>Malaria Journal</i> , 2015, 14, 306.	2.3	78
34	Delayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malaria – A Double-center Prospective Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 1921-1928.	4.0	77
35	Quinine plus clindamycin improves chemotherapy of severe malaria in children. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 1603-1605.	3.2	75
36	Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against <i>Plasmodium falciparum</i> and multidrug-resistant human leukemia cells. <i>European Journal of Medicinal Chemistry</i> , 2014, 75, 403-412.	5.5	74

#	ARTICLE	IF	CITATIONS
37	Loa loa "does it deserve to be neglected?. Lancet Infectious Diseases, The, 2014, 14, 353-357.	9.1	72
38	A Randomized Controlled Phase Ib Trial of the Malaria Vaccine Candidate GMZ2 in African Children. PLoS ONE, 2011, 6, e22525.	2.5	70
39	Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. European Journal of Medicinal Chemistry, 2014, 82, 204-213.	5.5	68
40	Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infectious Diseases, The, 2015, 15, 1409-1419.	9.1	67
41	Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. BMC Medicine, 2018, 16, 197.	5.5	65
42	Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment of Plasmodium falciparum Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases, 2005, 40, 1777-1784.	5.8	64
43	Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaré, Gabon. Vaccine, 2010, 28, 6698-6703.	3.8	63
44	Plasmodium vivax malaria in Duffy-negative individuals from Ethiopia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 328-331.	1.8	63
45	The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas. Journal of Infectious Diseases, 2013, 208, 479-488.	4.0	60
46	Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. American Journal of Tropical Medicine and Hygiene, 2018, 98, 508-515.	1.4	60
47	Randomized, Controlled, Assessor-Blind Clinical Trial To Assess the Efficacy of Single- versus Repeated-Dose Albendazole To Treat Ascaris lumbricoides, Trichuris trichiura, and Hookworm Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 2535-2540.	3.2	57
48	Safety and immunogenicity of rVSV-G-ZEBOV-GP Ebola vaccine in adults and children in Lambaré, Gabon: A phase I randomised trial. PLoS Medicine, 2017, 14, e1002402.	8.4	57
49	Mosquito Passage Dramatically Changes var Gene Expression in Controlled Human Plasmodium falciparum Infections. PLoS Pathogens, 2016, 12, e1005538.	4.7	54
50	Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2. Clinical Infectious Diseases, 2019, 69, 1377-1384.	5.8	53
51	Geschichte und Zukunft der Medizinischen Forschung am Albert Schweitzer Spital in Lambaré, Gabon. Wiener Klinische Wochenschrift, 2007, 119, 8-12.	1.9	52
52	IN VITRO ACTIVITY OF FERROQUINE (SAR97193) IS INDEPENDENT OF CHLOROQUINE RESISTANCE IN PLASMODIUM FALCIPARUM. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1178-1181.	1.4	49
53	Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine, 2012, 30, 7621-7624.	3.8	48
54	Limit of blank and limit of detection of Plasmodium falciparum thick blood smear microscopy in a routine setting in Central Africa. Malaria Journal, 2014, 13, 234.	2.3	48

#	ARTICLE	IF	CITATIONS
55	Novel approaches to whole sporozoite vaccination against malaria. <i>Vaccine</i> , 2015, 33, 7462-7468.	3.8	48
56	Hyperparasitemia and Blood Exchange Transfusion for Treatment of Children with Falciparum Malaria. <i>Clinical Infectious Diseases</i> , 1998, 26, 850-852.	5.8	47
57	Species and genotype diversity of Plasmodium in malaria patients from Gabon analysed by next generation sequencing. <i>Malaria Journal</i> , 2017, 16, 398.	2.3	46
58	Clinical and Parasitological Characteristics of Puerperal Malaria. <i>Journal of Infectious Diseases</i> , 2005, 191, 1005-1009.	4.0	44
59	Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial. <i>PLoS Medicine</i> , 2016, 13, e1001938.	8.4	44
60	Antimalarial Activity of the Myxobacterial Macrolide Chlorotonil A. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6378-6384.	3.2	43
61	The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. <i>PLoS ONE</i> , 2015, 10, e0135406.	2.5	42
62	Efficacy and Safety of Fosmidomycin + Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon. <i>Clinical Infectious Diseases</i> , 2018, 66, 1823-1830.	5.8	41
63	Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D. <i>PLoS ONE</i> , 2011, 6, e18559.	2.5	41
64	Hemolysis Is Associated with Low Reticulocyte Production Index and Predicts Blood Transfusion in Severe Malarial Anemia. <i>PLoS ONE</i> , 2010, 5, e10038.	2.5	40
65	A Simplified Intravenous Artesunate Regimen for Severe Malaria. <i>Journal of Infectious Diseases</i> , 2012, 205, 312-319.	4.0	38
66	In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays. <i>Malaria Journal</i> , 2009, 8, 79.	2.3	37
67	Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. <i>Future Microbiology</i> , 2015, 10, 1375-1390.	2.0	37
68	Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression. <i>PLoS Pathogens</i> , 2019, 15, e1007906.	4.7	36
69	Afucosylated Plasmodium falciparum-specific IgG is induced by infection but not by subunit vaccination. <i>Nature Communications</i> , 2021, 12, 5838.	12.8	36
70	High efficacy of short-term quinine-antibiotic combinations for treating adult malaria patients in an area in which malaria is hyperendemic. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 245-246.	3.2	35
71	Plasmodia express two threonine-peptidase complexes during asexual development. <i>Molecular and Biochemical Parasitology</i> , 2006, 148, 79-85.	1.1	35
72	Characterisation of a Tryptophan-rich Plasmodium falciparum antigen associated with merozoites. <i>Molecular and Biochemical Parasitology</i> , 2004, 137, 349-353.	1.1	34

#	ARTICLE	IF	CITATIONS
73	Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon. <i>Malaria Journal</i> , 2012, 11, 120.	2.3	34
74	IspC as Target for Antiinfective Drug Discovery: Synthesis, Enantiomeric Separation, and Structural Biology of Fosmidomycin Thia Isosters. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8151-8162.	6.4	34
75	Prospective Clinical and Molecular Evaluation of Potential <i>Plasmodium ovale curtisi</i> and <i>wallikeri</i> Relapses in a High-transmission Setting. <i>Clinical Infectious Diseases</i> , 2019, 69, 2119-2126.	5.8	34
76	Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. <i>Nature Communications</i> , 2021, 12, 2518.	12.8	34
77	The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants. <i>Malaria Journal</i> , 2015, 14, 72.	2.3	33
78	Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	33
79	Promoter Variants of the Human Mannose-Binding Lectin Gene Show Different Binding. <i>Biochemical and Biophysical Research Communications</i> , 2000, 275, 617-622.	2.1	31
80	±-Substituted ±-Oxa Isosteres of Fosmidomycin: Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 6566-6575.	6.4	31
81	2A and the Auxin-Based Degron System Facilitate Control of Protein Levels in <i>Plasmodium falciparum</i> . <i>PLoS ONE</i> , 2013, 8, e78661.	2.5	30
82	Burden of disease in Gabon caused by loiasis: a cross-sectional survey. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1339-1346.	9.1	30
83	Cord Blood Dendritic Cell Subsets in African Newborns Exposed to <i>Plasmodium falciparum</i> In Utero. <i>Infection and Immunity</i> , 2006, 74, 5725-5729.	2.2	29
84	Characterization of <i>Plasmodium</i> infections among inhabitants of rural areas in Gabon. <i>Scientific Reports</i> , 2019, 9, 9784.	3.3	28
85	Recombinase Polymerase Amplification and Lateral Flow Assay for Ultrasensitive Detection of Low-Density <i>Plasmodium falciparum</i> Infection from Controlled Human Malaria Infection Studies and Naturally Acquired Infections. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	28
86	The GMZ2 malaria vaccine: from concept to efficacy in humans. <i>Expert Review of Vaccines</i> , 2017, 16, 907-917.	4.4	27
87	Alterations of blood coagulation in controlled human malaria infection. <i>Malaria Journal</i> , 2016, 15, 15.	2.3	26
88	Human <i>Plasmodium vivax</i> diversity, population structure and evolutionary origin. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008072.	3.0	26
89	Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 36, 723-728.	3.0	25
90	Binding Modes of Reverse Fosmidomycin Analogs toward the Antimalarial Target IspC. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8827-8838.	6.4	25

#	ARTICLE	IF	CITATIONS
91	Distinct Helper T Cell Type 1 and 2 Responses Associated With Malaria Protection and Risk in RTS,S/AS01E Vaccinees. <i>Clinical Infectious Diseases</i> , 2017, 65, 746-755.	5.8	25
92	Mitochondrial localization of the threonine peptidase PfHslV, a ClpQ ortholog in <i>Plasmodium falciparum</i> . <i>International Journal for Parasitology</i> , 2010, 40, 1517-1523.	3.1	24
93	Broad-Spectrum Antimalarial Activity of Peptido Sulfonyl Fluorides, a New Class of Proteasome Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3576-3584.	3.2	24
94	Associations Between Helminth Infections, <i>Plasmodium falciparum</i> Parasite Carriage and Antibody Responses to Sexual and Asexual Stage Malarial Antigens. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 394-400.	1.4	24
95	Systems analysis and controlled malaria infection in Europeans and Africans elucidate naturally acquired immunity. <i>Nature Immunology</i> , 2021, 22, 654-665.	14.5	24
96	Antimalarial Activity of a Synthetic Endoperoxide (RBx-11160/OZ277) against <i>Plasmodium falciparum</i> Isolates from Gabon. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1535-1537.	3.2	23
97	In Vitro Activity of Mirincamycin (U24729A) against <i>Plasmodium falciparum</i> Isolates from Gabon. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 540-542.	3.2	23
98	Correlating efficacy and immunogenicity in malaria vaccine trials. <i>Seminars in Immunology</i> , 2018, 39, 52-64.	5.6	23
99	Malarial Parasites vs. Antimalarials: Never-Ending Rumble in the Jungle. <i>Current Molecular Medicine</i> , 2006, 6, 247-251.	1.3	22
100	Prodrugs of Reverse Fosmidomycin Analogues. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2025-2035.	6.4	22
101	<i>Schistosoma</i> co-infection protects against brain pathology but does not prevent severe disease and death in a murine model of cerebral malaria. <i>International Journal for Parasitology</i> , 2011, 41, 21-31.	3.1	21
102	Ivermectin Impairs the Development of Sexual and Asexual Stages of <i>Plasmodium falciparum</i> <i>In Vitro</i>. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
103	Effect of Anthelmintic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003768.	3.0	21
104	Assessment of LED fluorescence microscopy for the diagnosis of <i>Plasmodium falciparum</i> infections in Gabon. <i>Malaria Journal</i> , 2011, 10, 194.	2.3	20
105	Analysis of the <i>Plasmodium falciparum</i> proteasome using Blue Native PAGE and label-free quantitative mass spectrometry. <i>Amino Acids</i> , 2012, 43, 1119-1129.	2.7	20
106	The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016. <i>Vaccine</i> , 2017, 35, 7065-7069.	3.8	20
107	Emerging drugs for malaria. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 319-333.	2.4	19
108	Cytokine and chemokine profile of the innate and adaptive immune response of <i>Schistosoma haematobium</i> and <i>Plasmodium falciparum</i> single and co-infected school-aged children from an endemic area of Lambaré, Gabon. <i>Malaria Journal</i> , 2015, 14, 94.	2.3	19

#	ARTICLE	IF	CITATIONS
109	Bats are rare reservoirs of <i>Staphylococcus aureus</i> complex in Gabon. <i>Infection, Genetics and Evolution</i> , 2017, 47, 118-120.	2.3	19
110	Transcriptome profiling reveals functional variation in <i>Plasmodium falciparum</i> parasites from controlled human malaria infection studies. <i>EBioMedicine</i> , 2019, 48, 442-452.	6.1	19
111	High-throughput tri-colour flow cytometry technique to assess <i>Plasmodium falciparum</i> parasitaemia in bioassays. <i>Malaria Journal</i> , 2014, 13, 412.	2.3	18
112	Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Lambaré, Gabon: an open-label clinical trial. <i>Malaria Journal</i> , 2019, 18, 424.	2.3	18
113	<i>Schistosoma haematobium</i> infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon. <i>Parasites and Vectors</i> , 2019, 12, 577.	2.5	18
114	Molecular Epidemiology of <i>Mansonella</i> Species in Gabon. <i>Journal of Infectious Diseases</i> , 2021, 223, 287-296.	4.0	18
115	In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in <i>Plasmodium falciparum</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2006, 75, 1178-81.	1.4	18
116	Threonine peptidases as drug targets against malaria. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 365-378.	3.4	17
117	In Vitro Activity of Fluorescent Dyes against Asexual Blood Stages of <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5982-5985.	3.2	17
118	Development and evaluation of a multiplex screening assay for <i>Plasmodium falciparum</i> exposure. <i>Journal of Immunological Methods</i> , 2012, 384, 62-70.	1.4	17
119	Sporozoite Route of Infection Influences In Vitro Gene Transcription of <i>Plasmodium falciparum</i> Parasites From Controlled Human Infections. <i>Journal of Infectious Diseases</i> , 2016, 214, 884-894.	4.0	17
120	Prospective Clinical Trial Assessing Species-Specific Efficacy of Artemether-Lumefantrine for the Treatment of <i>Plasmodium malariae</i> , <i>Plasmodium ovale</i> , and Mixed <i>Plasmodium</i> Malaria in Gabon. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	17
121	Immunosuppression in Malaria: Do <i>Plasmodium falciparum</i> Parasites Hijack the Host?. <i>Pathogens</i> , 2021, 10, 1277.	2.8	17
122	Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions - a prospective multicenter cohort study. <i>BMC Medicine</i> , 2015, 13, 125.	5.5	16
123	Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae. <i>Vaccine</i> , 2017, 35, 3474-3481.	3.8	16
124	Life-span of in vitro differentiated <i>Plasmodium falciparum</i> gametocytes. <i>Malaria Journal</i> , 2017, 16, 330.	2.3	16
125	Novel approaches in antimalarial drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1325-1337.	5.0	15
126	Effect of Fluorescent Dyes on In Vitro-Differentiated, Late-Stage <i>Plasmodium falciparum</i> Gametocytes. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7398-7404.	3.2	15

#	ARTICLE	IF	CITATIONS
127	Workshop report: Malaria vaccine development in Europe“preparing for the future. <i>Vaccine</i> , 2015, 33, 6137-6144.	3.8	15
128	Growth Rate of <i>Plasmodium falciparum</i> : Analysis of Parasite Growth Data from Malaria Volunteer Infection Studies. <i>Journal of Infectious Diseases</i> , 2020, 221, 963-972.	4.0	15
129	Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. <i>Tropical Medicine and International Health</i> , 2020, 25, 380-386.	2.3	15
130	Haematological and biochemical reference intervals for infants and children in Gabon. <i>Tropical Medicine and International Health</i> , 2011, 16, 343-348.	2.3	14
131	Development of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches Médicales de Lambaréon (CERMEL), Gabon. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 500-508.	1.9	14
132	Increase in annexin V-positive B cells expressing LILRB1/ILT2/CD85j in malaria. <i>European Cytokine Network</i> , 2006, 17, 175-80.	2.0	14
133	Analysis of polymorphic sites in the promoter of the nitric oxide synthase 2 gene. <i>Biochemical and Biophysical Research Communications</i> , 2005, 335, 1123-1131.	2.1	13
134	Humoral immune response to <i>Plasmodium falciparum</i> vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia. <i>Malaria Journal</i> , 2013, 12, 51.	2.3	13
135	Blood Schizontocidal and Gametocytocidal Activity of 3-Hydroxy-N ² -arylidene propanehydrazonamides: A New Class of Antiplasmodial Compounds. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7971-7976.	6.4	13
136	Neutrophil alterations in pregnancy-associated malaria and induction of neutrophil chemotaxis by <i>Plasmodium falciparum</i> . <i>Parasite Immunology</i> , 2017, 39, e12433.	1.5	13
137	Use of Capillary Blood Samples Leads to Higher Parasitemia Estimates and Higher Diagnostic Sensitivity of Microscopic and Molecular Diagnostics of Malaria Than Venous Blood Samples. <i>Journal of Infectious Diseases</i> , 2018, 218, 1296-1305.	4.0	13
138	Regional Variation of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales, Fluoroquinolone-Resistant <i>Salmonella enterica</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> Among Febrile Patients in Sub-Saharan Africa. <i>Frontiers in Microbiology</i> , 2020, 11, 567235.	3.5	13
139	Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009361.	3.0	13
140	New method to quantify erythrophagocytosis by autologous monocytes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2007, 71A, 258-264.	1.5	12
141	In vitro activity of tigecycline in <i>Plasmodium falciparum</i> culture-adapted strains and clinical isolates from Gabon. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 587-589.	2.5	12
142	Carriage of encapsulated bacteria in Gabonese children with sickle cell anaemia. <i>Clinical Microbiology and Infection</i> , 2013, 19, 235-241.	6.0	12
143	Recognition of <i>Plasmodium falciparum</i> mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon. <i>Malaria Journal</i> , 2017, 16, 176.	2.3	11
144	Behavioural and clinical predictors for Loiasis. <i>Journal of Global Health</i> , 2018, 8, 010413.	2.7	11

#	ARTICLE	IF	CITATIONS
145	DNA recovery from archived RDTs for genetic characterization of <i>Plasmodium falciparum</i> in a routine setting in Lambaré, Gabon. <i>Malaria Journal</i> , 2019, 18, 336.	2.3	11
146	Experimental infections in humans—historical and ethical reflections. <i>Tropical Medicine and International Health</i> , 2019, 24, 1384-1390.	2.3	11
147	A retinal model of cerebral malaria. <i>Scientific Reports</i> , 2019, 9, 3470.	3.3	11
148	Nycteria and <i>Polychromophilus</i> parasite infections of bats in Central Gabon. <i>Infection, Genetics and Evolution</i> , 2019, 68, 30-34.	2.3	11
149	Validity and reliability of methods to microscopically detect and quantify malaria parasitaemia. <i>Tropical Medicine and International Health</i> , 2018, 23, 980-991.	2.3	10
150	Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection. <i>Frontiers in Immunology</i> , 2021, 12, 625712.	4.8	10
151	Extended follow-up of children in a phase 2b trial of the GM22 malaria vaccine. <i>Vaccine</i> , 2021, 39, 4314-4319.	3.8	10
152	A single-dose antihelminthic treatment does not influence immunogenicity of a meningococcal and a cholera vaccine in Gabonese school children. <i>Vaccine</i> , 2016, 34, 5384-5390.	3.8	9
153	Design and Synthesis of Novel Anti-Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit. <i>Archiv Der Pharmazie</i> , 2017, 350, 1600347.	4.1	9
154	Effect of immune regulatory pathways after immunization with GM22 malaria vaccine candidate in healthy lifelong malaria-exposed adults. <i>Vaccine</i> , 2020, 38, 4263-4272.	3.8	9
155	In vitro activity of new artemisinin derivatives against <i>Plasmodium falciparum</i> clinical isolates from Gabon. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 485-488.	2.5	8
156	Effect of IL-15 on IgG versus IgE antibody-secreting cells in vitro. <i>Journal of Immunological Methods</i> , 2012, 375, 7-13.	1.4	8
157	Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients. <i>Malaria Journal</i> , 2017, 16, 188.	2.3	8
158	Impact of Helminth Infections during Pregnancy on Vaccine Immunogenicity in Gabonese Infants. <i>Vaccines</i> , 2020, 8, 381.	4.4	8
159	Unbiased metagenomic next-generation sequencing of blood from hospitalized febrile children in Gabon. <i>Emerging Microbes and Infections</i> , 2020, 9, 1242-1244.	6.5	8
160	In vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite <i>Plasmodium falciparum</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 93-97.	2.2	8
161	<i>Plasmodium falciparum</i> 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. <i>Nature Communications</i> , 2022, 13, .	12.8	8
162	In vitro growth of <i>Plasmodium falciparum</i> in neonatal blood. <i>Malaria Journal</i> , 2014, 13, 436.	2.3	7

#	ARTICLE	IF	CITATIONS
163	Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007324.	3.0	7
164	Causes of fever in Gabonese children: a cross-sectional hospital-based study. <i>Scientific Reports</i> , 2020, 10, 2080.	3.3	7
165	Lessons from a modern review of the smallpox eradication files. <i>Journal of the Royal Society of Medicine</i> , 2015, 108, 473-477.	2.0	6
166	Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111555.	5.5	6
167	8-Aminoquinolines with an Aminoxyalkyl Side Chain Exert in vitro Dual-Stage Antiplasmodial Activity. <i>ChemMedChem</i> , 2019, 14, 501-511.	3.2	6
168	Genetic Diversity of Enteric Viruses in Children under Five Years Old in Gabon. <i>Viruses</i> , 2021, 13, 545.	3.3	6
169	Molecular epidemiology of respiratory syncytial virus in children in sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2021, 26, 810-822.	2.3	6
170	Molecular surveillance and genetic divergence of rotavirus A antigenic epitopes in Gabonese children with acute gastroenteritis. <i>EBioMedicine</i> , 2021, 73, 103648.	6.1	6
171	Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection. <i>JCI Insight</i> , 2022, 7, .	5.0	6
172	Reduced CD3/TCR complex expression leads to immunosuppression during <i>Plasmodium falciparum</i> malaria. <i>Parasitology Research</i> , 2009, 104, 575-582.	1.6	5
173	A flow cytometry-based workflow for detection and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed individuals. <i>Malaria Journal</i> , 2012, 11, 367.	2.3	5
174	Real-time measurement of <i>Plasmodium falciparum</i> -infected erythrocyte cytoadhesion with a quartz crystal microbalance. <i>Malaria Journal</i> , 2016, 15, 317.	2.3	5
175	Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 635.	1.6	5
176	3-Hydroxy-propanamidines, a New Class of Orally Active Antimalarials Targeting <i>Plasmodium falciparum</i> . <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3035-3047.	6.4	5
177	Assessment of malaria transmission intensity and insecticide resistance mechanisms in three rural areas of the Moyen Ogooué Province of Gabon. <i>Parasites and Vectors</i> , 2022, 15, .	2.5	5
178	Clonal evolution and TCR specificity of the human T _{FH} cell response to <i>Plasmodium falciparum</i> CSP. <i>Science Immunology</i> , 2022, 7, .	11.9	5
179	3-Hydroxy-N ² -arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure <i>P. berghei</i> Infected Mice When Administered Perorally. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6036-6044.	6.4	4
180	Prevalence of Pathogens in Young Children Presenting to Hospital with Diarrhea from Lambaré, Gabon. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 254-260.	1.4	4

#	ARTICLE	IF	CITATIONS
181	PAD4 controls chemoattractant production and neutrophil trafficking in malaria. <i>Journal of Leukocyte Biology</i> , 2021, , .	3.3	4
182	Boromycin has Rapid-Onset Antibiotic Activity Against Asexual and Sexual Blood Stages of <i>Plasmodium falciparum</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 802294.	3.9	4
183	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched caseâ€“control study. <i>ELife</i> , 2022, 11, .	6.0	4
184	An efficient singleâ€“cell based method for linking human T cell phenotype to T cell receptor sequence and specificity. <i>European Journal of Immunology</i> , 2022, 52, 237-246.	2.9	3
185	Efficacy, T cell activation and antibody responses in accelerated <i>Plasmodium falciparum</i> sporozoite chemoprophylaxis vaccine regimens. <i>Npj Vaccines</i> , 2022, 7, .	6.0	3
186	Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial. <i>Malaria Journal</i> , 2022, 21, .	2.3	3
187	Parasites and pregnancy. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 681-684.	1.9	2
188	New medicines for malaria. <i>Wiener Klinische Wochenschrift</i> , 2010, 122, 19-22.	1.9	2
189	Immunological tests to diagnose active tuberculosis. <i>Journal of Internal Medicine</i> , 2009, 265, 159-162.	6.0	1
190	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 106, 265-268.	3.3	1
191	SAFETY OF RVSV EBOLA VACCINE, AFTER 6 MONTHS FOLLOW-UP, IN ADULTS: A PHASE 1 TRIAL CONDUCTED IN LAMBARÃ‰NÃ‰, GABON. <i>BMJ Global Health</i> , 2017, 2, A67.1-A67.	4.7	0